PepJunkie Home of the Peptonauts
More
HomeThe PulseAtlasDiscussHunter-GathererResearchProfileSearch

Research

Leuprolide (Leuprorelin) — living evidence map

The Atlas page holds the claims; this is how its evidence evolved.

Summary

Leuprorelin (leuprolide acetate) is a GnRH analogue that causes a brief initial rise in gonadotrophins and then, with continued use, pituitary desensitisation and suppressed sex hormones; it is used in advanced prostate cancer, endometriosis and central precocious puberty. · pmid:7533699

In the 48-week JASMITT trial in 199 men with spinal and bulbar muscular atrophy, leuprorelin did not significantly improve the primary swallowing measure against placebo. · pmid:20691641

Identity

PubChem CID 657181: Leuprolide, C59H84N16O12, 1209.4 g/mol. · pubchem:657181

CAS registry number 53714-56-0. · pubchem:657181

Where the evidence actually sits

Established100%

Proportion of the 2 claims about Leuprolide (Leuprorelin) standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.

Living evidence history

Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. (1994) · establishedEfficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. (2010) · established19942010

2 resolved citations, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.

Structure

No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Leuprolide (Leuprorelin) yet.

Dose evidence, rung by rung

A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.

  1. Approved-label dose · a resolved regulatory document names a labelled dose

    nothing resolved on this rung

  2. Studied human doses · resolved human studies at the established tier
    • Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. · pmid 20691641 · 2010
    • Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. · pmid 7533699 · 1994
  3. Observational evidence · resolved human data at the emerging tier: thin, or contested

    nothing resolved on this rung

  4. Community-reported protocols · protocol propositions from distinct members, counted once per human

    nothing resolved on this rung

  5. Preclinical evidence · resolved animal, cell or mechanistic work

    nothing resolved on this rung

2 resolved citations, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.